News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Guidance
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
InspireMD, Inc. reported increased revenues for the first half of 2026, up 56.3% to $5.17 million, driven by U.S. CGuard Prime sales and international growth, despite a voluntary recall of CGuard Prime impacting quarterly revenue and gross margin. The company posted a significant net …
HC Wainwright analysts have increased their Q4 2027 earnings per share forecast for LifeMD to $0.17 from $0.15, while maintaining a "Buy" rating and a $9 price target. Despite this, analyst sentiment remains mixed with a "Moderate Buy" consensus rating but several recent downgrades. …
LifeMD, Inc. (NASDAQ:LFMD) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $7.57. Despite this, the company reported a slight miss on quarterly earnings and revenue expectations, posting a loss of $0.16 per share and $47.28 …
LifeMD, Inc. published its Q2 2026 earnings call presentation, reporting an EPS of -$0.15, missing estimates by $0.10, and revenue of $47.28M, down 24.01% year-over-year and missing estimates by $1.82M. The presentation is provided for investors to review the company's financial performance.
InspireMD, Inc. will release its second quarter 2026 financial results on August 17, 2026, followed by a conference call and webcast at 8:30 a.m. ET. The company, known for its CGuard Prime carotid stent system, will discuss its financial performance and operational updates, including …
InspireMD (Nasdaq: NSPR) announced it will release its second quarter 2026 financial results on Monday, August 17, 2026. The company will host a conference call and live audio webcast at 8:30 a.m. Eastern Time to discuss the results and recent highlights. Investors can participate …
Insiders at InspireMD bought US$420.8k worth of stock over the last year, but despite a recent 14% stock gain, they are still down US$161k on their purchases. While there was some insider selling, the net insider activity over the year indicates more buying than …
Renaissance Technologies LLC reduced its stake in LifeMD, Inc. by 25.4% in the first quarter, selling 380,000 shares and retaining over 1.1 million shares. Despite this, analysts generally hold a "Moderate Buy" consensus for LifeMD, with an average price target of $7.57, though some …
InspireMD (Nasdaq: NSPR) has granted 221,666 restricted shares to a new non-executive employee as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These shares, granted under the company's 2024 Inducement Plan with a grant date of August 3, 2026, will vest …
InspireMD, Inc. announced that its Compensation Committee approved inducement grants totaling 221,666 shares of restricted stock to a new non-executive employee. These grants were made outside of the company's 2021 Equity Incentive Plan but under its 2024 Inducement Plan, in accordance with Nasdaq Listing …
HC Wainwright has lowered its price target for LifeMD (NASDAQ:LFMD) to $9.00 from $10.00 but maintained a "buy" rating, indicating a potential upside of 164.71%. The revision follows LifeMD's recent quarterly results, which missed analyst expectations with a reported loss of $0.16 per share …
This article provides an earnings forecast for InspireMD Inc (NSPR), detailing its current earnings forecast score, average price target from analysts, and a comparison with peers. It highlights expected revenue, EPS for past and upcoming quarters, and the overall analyst rating, which leans towards …
LifeMD, Inc.'s average 12-month price target has been reduced from $9.88 to $9 by 8 analysts, with forecasts ranging from $7 to $15 per share. Despite the cut, this new target still suggests a substantial 145% potential upside from its Aug. 5 closing price. …
LifeMD Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief announcement of these financial results. To access the full details, readers are directed to the complete article available on TradingView.
LifeMD, Inc. reported its second-quarter 2026 results, showing a revenue of $47.28 million, a 3.6% decrease year-over-year, and a net loss of $7.86 million, significantly wider than the previous year's loss. The diluted loss per share was $(0.16). Despite a decline in online product …
This article provides an AI-driven analysis of LifeMD Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ: LFMDP), noting a neutral sentiment and a wait-and-see approach. It highlights an exceptional 12.0:1 risk-reward setup targeting a 3.6% gain, with specific trading strategies for position trading, …
LifeMD, Inc. announced its Q2 2026 financial results, reporting revenues of $47.3 million and a sequential improvement in adjusted EBITDA loss to $3.5 million. The company is transitioning its weight management program to branded GLP-1 therapies, which now account for 95% of new patients, …
LifeMD (NASDAQ:LFMD) reported its quarterly earnings, missing analyst expectations with an adjusted EPS of negative $0.16 against a consensus of negative $0.15, and revenue of $47.28 million, falling short of the $49.16 million estimate. The telehealth company also reduced its full-year 2026 guidance due …
LifeMD (NASDAQ:LFMD) reported disappointing Q2 2026 results, missing both revenue and non-GAAP EPS consensus estimates. The virtual care and pharmacy services company posted revenue of $47.3 million against a $50.1 million consensus, and a non-GAAP loss per share of $0.16 compared to an expected …
LifeMD reported Q2 2026 telehealth revenue of $47.3 million, a 4% year-over-year decrease, though within guidance, as it transitions weight-management patients to branded GLP-1 therapies and longer subscriptions. The company increased active subscribers by 20% to approximately 356,000, and gross margin expanded to 89%. …
LifeMD reported a 3% year-over-year revenue decline to $47.3 million in Q2 2026, while its adjusted EBITDA swung to a $3.5 million loss, primarily due to higher customer acquisition costs and a strategic shift to branded GLP-1 therapies. Despite the revenue dip, gross margin …
LifeMD (LFMD) reported a Q2 revenue miss of $47.3 million against an analyst forecast of $49.15 million, alongside an adjusted EBITDA loss and a lowered full-year 2026 outlook, causing shares to drop over 17% in after-hours trading. Despite the financial setbacks, the company highlighted …
LifeMD, Inc. (LFMD) reported a Q2 loss of $0.16 per share, which was an earnings surprise of +20.00% compared to the Zacks Consensus Estimate of a $0.2 loss. However, the company missed revenue estimates, posting $47.28 million against an estimated $49.10 million. Despite outperforming …
LifeMD presented an investor overview in August 2026, highlighting its AI-enabled virtual care platform and growth strategy, despite second-quarter results missing Wall Street expectations. The company's shares fell significantly following the earnings release, nearing its 52-week low. The presentation emphasized LifeMD's transformation into a …
LifeMD, Inc. reported a Q2 2026 net loss of $15.96 million from continuing operations, despite revenues of $47.3 million, a slight decrease from the prior year. The company maintains a strong liquidity position with $25.1 million in cash, no outstanding debt, and an undrawn …
LifeMD Inc is projected to report a loss of 15 cents per share, according to this earnings preview. The article indicates that this financial expectation comes from Refinitiv. Full details are available to TradingView subscribers.
This article provides a comprehensive stock analysis of InspireMD Inc (NSPR) by TradingKey, assigning it a "relatively very healthy" fundamental score and high growth potential, though its valuation is deemed "fairly valued." Key insights include high institutional ownership, multiple "Buy" ratings from analysts with …
InspireMD has eliminated the position of Chief Commercial Officer, effective July 31, 2026, with Shane Gleason's employment ending on that date. This change signals a potential shift in the company's commercial strategy or organizational priorities. While the most recent analyst rating is a Buy …
Search by ticker symbol or company name and select a result to open its chart.